This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Women's Health  • Women's Health, Other  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Col and colleagues¹ provide an excellent example of the use of a clinical decision model to target short-term hormone therapy (HT) for the treatment of menopausal symptoms in light of recent data from the Women’s Health Initiative trial. However, while the decision model focuses on rare but serious adverse effects of short-term HT, it fails to account for less serious but more common adverse effects requiring medical attention. For example, Anderson and colleagues² report that, among women not scheduled for routine endometrial biopsy as part of the Women’s Health Initiative study protocol, 33% of those assigned to HT had an endometrial biopsy, compared with 6% among those assigned to placebo (P<.001). Of women receiving at least 1 endometrial biopsy, 38% (13% overall) had more than 1 biopsy in the HT group, compared with 16% (1% overall) in the placebo group. Similarly large differences in rates of transvaginal uterine . . . [Full Text of this Article]

AUTHOR INFORMATION
Robert L. Ohsfeldt, PhD

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?